Perficient, Inc. (PRFT) Scheduled to Post Quarterly Earnings on Wednesday

Perficient, Inc. (NASDAQ:PRFT) is scheduled to be announcing its earnings results before the market opens on Wednesday, November 1st. Analysts expect the company to announce earnings of $0.34 per share for the quarter. Perficient has set its Q3 guidance at $0.32-$0.34 EPS and its FY17 guidance at $1.19-$1.29 EPS.

Perficient (NASDAQ:PRFT) last posted its quarterly earnings results on Thursday, August 3rd. The digital transformation consultancy reported $0.29 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.29. The firm had revenue of $117.00 million during the quarter, compared to analyst estimates of $119.21 million. Perficient had a return on equity of 7.42% and a net margin of 3.08%. Perficient’s quarterly revenue was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.28 EPS. On average, analysts expect Perficient to post $0.95 EPS for the current fiscal year and $1.11 EPS for the next fiscal year.

Perficient, Inc. (NASDAQ PRFT) opened at 19.04 on Tuesday. The stock has a market cap of $668.63 million, a price-to-earnings ratio of 46.21 and a beta of 0.89. Perficient, Inc. has a 52-week low of $14.15 and a 52-week high of $20.22. The stock has a 50 day moving average price of $19.24 and a 200 day moving average price of $18.10.

In other Perficient news, Director Ralph C. Derrickson sold 7,900 shares of the stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $17.64, for a total value of $139,356.00. Following the completion of the sale, the director now directly owns 32,747 shares in the company, valued at $577,657.08. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Paul E. Martin sold 6,082 shares of the stock in a transaction dated Wednesday, October 11th. The shares were sold at an average price of $20.20, for a total value of $122,856.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 88,847 shares of company stock valued at $1,739,758. 3.70% of the stock is currently owned by company insiders.

A number of equities research analysts recently weighed in on PRFT shares. Zacks Investment Research cut Perficient from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub cut Perficient from a “hold” rating to a “sell” rating in a research note on Saturday, July 8th. Finally, Maxim Group set a $20.00 price objective on Perficient and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Perficient has an average rating of “Buy” and an average target price of $20.67.

TRADEMARK VIOLATION NOTICE: “Perficient, Inc. (PRFT) Scheduled to Post Quarterly Earnings on Wednesday” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at

About Perficient

Perficient, Inc is an information technology and management consulting firm. The Company’s solutions include business intelligence and analytics, commerce, content management, custom applications, platform implementations, portals and collaboration, business integration and application program interfaces, management consulting, business process management, and customer relationship management, among others.

Earnings History for Perficient (NASDAQ:PRFT)

What are top analysts saying about Perficient Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Perficient Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit